This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Affymetrix's CEO Discusses Q4 2011 Results - Earnings Call Transcript

We've made significant changes to the structure of our commercial organization, and made a number of key hires, as well. This includes a new head of global commercial operations, Vice Presidents of both Global Marketing and Regulatory, as well as new commercial leadership in Europe and Japan. We're making a steady progress in redirecting the business and laying the groundwork for a return to growth.

For 2012, we are executing against the focus set of commercial goals that include: first, stabilizing our expression business. This includes arrays, low-plex solutions and single cell and tissue products. Increasing our -- secondly, increasing our market share in genotyping, particularly targeted applications. Third, building critical mass toward a market-leading position in cytogenetics. And last, driving continued growth on our life science reagents business.

I'd like to highlight some quarterly accomplishments and expectations against each of these initiatives, starting with our expression business unit. Expression constitutes about 45% of our revenue, and we took some important steps towards stabilizing the business in the fourth quarter.

One of our primary goals is to offset the decline in our IVT revenue. We intend to do this by adding new products to our array-based expression portfolio and rejuvenating our Panomics mid-plex cell and tissue assays. We anticipate that our overall expression business will decline by 5% to 10% in 2012. But we also see emerging opportunities that will help offset the decline of our IVT arrays. This is a significant challenge for us. As you're aware, we are focusing on the area with new products for preclinical and clinical applications.

And I want to give you a short progress report on some of our activities in this area. We recently entered into an exclusive agreement with Genisphere to offer the company's FlashTag Biotin reagents. These microRNA reagents enables streamlined target prep methods for high-quality and reproducibility, and strengthen our industry-leading position in array-based gene expression. microRNA is one of the fastest growing applications in gene expression, and represents an important new revenue stream for Affymetrix, one that we expect will grow significantly, as we continue to introduce new content.

3 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,689.86 -56.12 -0.32%
S&P 500 2,103.84 -4.79 -0.23%
NASDAQ 5,128.2810 -0.5040 -0.01%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs